APOC3 Antibody, FITC conjugated

Code CSB-PA12197C0Rb
Size US$299
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) APOC3 Polyclonal antibody
Uniprot No. P02656
Target Names APOC3
Alternative Names APOC3 antibody; APO C3 antibody; Apo CIII antibody; Apo-CIII antibody; APOC 3 antibody; ApoC III antibody; ApoC-III antibody; APOC3 antibody; APOC3_HUMAN antibody; ApoCIII antibody; Apolipoprotein C III antibody; Apolipoprotein C-III antibody; Apolipoprotein C3 antibody; ApolipoproteinCIII antibody; MGC150353 antibody
Raised in Rabbit
Species Reactivity Human
Immunogen Recombinant Human Apolipoprotein C-III protein (21-99AA)
Immunogen Species Homo sapiens (Human)
Conjugate FITC
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form Liquid
Tested Applications ELISA
Protocols ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma
Gene References into Functions
  1. ApoCIII may mediate the effects of ANGPTL8 on triglyceride metabolism. PMID: 30021607
  2. The S2 allele of the SstI polymorphism in the apoC3 gene is associated with plasma apoCIII levels in the Li population. In combination with unfavorable lipid profiles, this might contribute to susceptibility to atherosclerosis. PMID: 29162127
  3. Data indicate effects of a loss-of-function Ala43Thr substitution in apolipoprotein C3 (APOC3) rs147210663. PMID: 29237685
  4. the present study demonstrates major modifications of the proteome in patients with cerebral lacunar infarction(LACI). The ApoC-III enrichment of the HDL of patients with cerebral lacunar infarction may cause a reduction in the anti-inflammatory ability of HDL, which may contribute to the progression of the disease PMID: 29115584
  5. C3(QK) variant is a gain-of-function mutation that can stimulate VLDL1 production, through enhanced DNL PMID: 28887372
  6. Review/Meta-analysis: APOC3 polymorphisms were not association with increased risk of ischemic stroke PMID: 28865324
  7. rs4225 in the 3'-UTR of APOC3 might contribute to the risk of coronary heart disease by interfering with miR-4271 binding. PMID: 27624799
  8. APOC3 modulates HDL structure and function, while it selectively promotes BAT metabolic activation PMID: 28701354
  9. apoC-III potently inhibits triglyceride hydrolysis when LPL is bound to GPIHBP1 PMID: 28694296
  10. apolipoprotein C3 and atherosclerosis PMID: 28441154
  11. intestinal apoC-III overexpression results in the secretion of smaller, less dense chylomicron particles along with reduced triacylglycerol secretion from the intestine PMID: 28159868
  12. Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition PMID: 28159869
  13. No evidence that APOC3 3'UTR variant SstI modulates expression of liver/intestinal miRNAs in hypertriglyceridemia. PMID: 27794214
  14. A rare variant in APOC3(rs138326449) has been associated with triglyceride, very low-density lipoprotein, and high-density lipoprotein levels, as well as risk of coronary heart disease. Effects are unlikely to be solely predictable by the action of APOC3 through LPL. PMID: 27114411
  15. both human APOC3 A43T heterozygotes and mice expressing human APOC3 A43T display markedly reduced circulating apoC-III levels. In mice, this reduction is due to impaired binding of A43T apoC-III to lipoproteins and accelerated renal catabolism of free apoC-III. PMID: 28825717
  16. Gene-level meta-analysis with other studies reporting burden signals at APOC3 provides robust evidence for a replicable cardioprotective rare variant aggregation PMID: 27146844
  17. studied the associations of apoC-III, endothelial function and diabetic peripheral neuropathy PMID: 28641786
  18. Plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C-III (apoC3) and small dense low density lipoprotein cholesterol (sdLDL-C) showed significant interactions with current dyslipidemias, and were predictive in the screening. PMID: 27713142
  19. Novel sequencing techniques are detecting rare variants with larger effect sizes (eg, APOC3) , which may further improve on Cardiovascular disease risk prediction. PMID: 27650930
  20. The APOC3 rs2070666 A allele is a risk factor for NAFLD independent of obesity, dyslipidemia, and PNPLA3 rs738409, and it might contribute to increased liver fat content in Chinese Han population. PMID: 27059980
  21. plasma levels significantly associated with the development and severity of metabolic syndrome PMID: 28245894
  22. ApoC-III levels are significantly associated with incident coronary artery disease risk. Elevated levels of remnant lipoproteins, small dense low-density lipoprotein, and low-grade inflammation may explain this association. PMID: 28473441
  23. The authors findings confirm an association of APOC3 with gout. PMID: 27094595
  24. Accumulating evidence indicates that apolipoprotein C-III is a multifaceted protein which not only regulates triglyceride metabolism, but also participates in the atherosclerotic lesion formation and several other pathological processes involved in atherosclerosis. PMID: 27770802
  25. Our results showed that APOC3 was closely associated with the inflammatory process in ECs, and that this process was characterized by the increased expression of TNF-alpha. Inflammatory processes further disrupted the tight junctions (TJs) between HUVECs by causing increased expression of JAM-1. PMID: 27619170
  26. review of its clinical implications and targeted therapies[review] PMID: 27318213
  27. Transgenic mice expressing human APOC3in the C57BL/6J background have been described. The study found that hypertriglyceridemia per se is not an independent risk factor for beta cell dysfunction in ApoC3 transgenic mice. PMID: 27226540
  28. ApoA-1 and ApoC-III may be used as differentiating and predictive markers for SCLC [ small cell lung cancer ]. PMID: 26996551
  29. The results of our meta-analysis point to a strong link between both APOA5 -1131T>C and APOC3 -455T>C polymorphisms and an increased risk of coronary heart disease . PMID: 26782469
  30. HDL-apoCIII has a significant and positive association with coronary heart disease . PMID: 26452348
  31. APOA5 -1131 T > C and APOC3 -455 T > C SNPs may play potent roles in the development and progression of coronary heart disease. (Meta-analysis) PMID: 26387083
  32. D25V apolipoprotein C-III is a new human amyloidogenic protein and the first conferring cardioprotection. PMID: 26790392
  33. The current body of literature includes several methodologically sound studies that together provide consistent evidence for an association of cardiovascular events with blood apoC-III level in total plasma or in VLDL and LDL. PMID: 26228667
  34. 3238C>G polymorphism of ApoC3 gene appears to augment the propensity to develop T2DM, while -482C>T to negatively affect lipid metabolism in Saudi subjects. PMID: 26247234
  35. Data suggest that apolipoprotein C-III (ApoCIII) adopts an alternate helical conformation on the bilayer which could have functional implications. PMID: 26301570
  36. Lipoprotein associated phospholipase A2 activity and apolipoprotein C3 loss-of-function variants are involved in cardiovascular disease PMID: 26117401
  37. genetic variants associated with elevated triglycerides and VLDL and risk of intracerebral hemorrhage PMID: 25994187
  38. meta-analysis demonstrates significant association between rs5128 polymorphism and higher levels of APOC3, TG, TC and LDL-C PMID: 25928461
  39. ApoC3 Sst I and T-455C polymorphisms might be associated with coronary heart disease risk. PMID: 24430880
  40. The objective of this study was to evaluate the reliability of MALDI-TOF mass spectrometry of apoC-III for the detection and characterization of congenital disorders of glycosylation-associated O-glycan defects. PMID: 25641685
  41. APOC3 loss-of- function mutation carriers had reduced plasma triglycerides, higher HDL-C,and a decreased burden of coronary arterial calcification. PMID: 26516010
  42. In examined Kyrgyz ethnic population the most frequent was heterozygous TC genotype of T455C polymorphism of apo C-III. PMID: 26625519
  43. In persons with T2DM, increased plasma ApoC-III is associated with higher triglycerides, less favorable cardiometabolic phenotypes, and higher coronary artery calcification, a measure of subclinical atherosclerosis. PMID: 26069232
  44. Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. PMID: 24966274
  45. The polymorphism T-455C in APOC3 gene and elevated serum triglycerides were associated with NAFLD. However, we did not find a significant association of C-482T polymorphism (rs2854117) of APOC3 gene with NAFLD. PMID: 25319715
  46. these results suggest that plasma apoA-I could be a sensitive Alzheimer's disease biomarker and individuals with low plasma levels of apoC-III are at risk for Alzheimer's disease. PMID: 24685634
  47. APOC3 R19X allele participants had approximately half the triglyceride levels, >20% higher high-density lipoprotein cholesterol levels, and lower low-density lipoprotein cholesterol levels compared with noncarrier participants. PMID: 25363704
  48. The APOC3 3238 G allele might contribute to an increased risk of coronary artery disease as a result of its effect on triglycerides and VLDL-cholesterol metabolism. PMID: 25380998
  49. Confirming the negative role of APOC-III in TG metabolism can be used as therapeutic target for the management of hypertriglyceridemia and reduction of ischemic cardiovascular events. PMID: 25994465
  50. APOC3 (-455T>C) genetic variation is involved in the susceptibility to developing NAFLD in the Southern Chinese Han population. PMID: 25320541
  51. analysis of a diet-gene interaction between APOC3 rs5128 polymorphism and the Western dietary pattern in relation to metabolic syndrome risk PMID: 25301527
  52. The two polymorphisms of the APOC3 gene are not associated with a risk of NAFLD, or with lipid profiles, IR and oxidative stress in the Chinese Han population PMID: 24707151
  53. APOC3 T-455CC genotype is relatively prevalent in HIV infected cohort in nothern South Africa. PMID: 24972136
  54. Heterozygosity for APOC3 mutations results in high HDL-C and low TGs and apoCIII levels. PMID: 23701270
  55. R19X variant in APOC3 increased high-density lipoprotein and decreased triglycerides levels in Greek population. PMID: 24343240
  56. We have shown that variants of PNPLA3 and APOC3 independently and in an additive manner contribute to elevated hepatic triglyceride content in Hispanic children. PMID: 23804528
  57. Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have a reduced risk of coronary heart disease. PMID: 24941081
  58. Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease. PMID: 24941082
  59. Elevated concentrations of Apo CIII are associated with an increase of thrombin activity to an extent comparable with the carriership of G20210A gene variant and mainly modulating the thrombin generation. PMID: 24242684
  60. No association between APOC3 gene variant rs2854117 and histological or metabolic parameters of non-alcoholic fatty liver disease was found. PMID: 23512881
  61. APOC3 polymorphisms had no effect on the development of steatosis and no influence on the PNPLA3 polymorphism. PMID: 23808989
  62. Lipoprotein lipase/APOC3 genotype determines severity of coronary artery disease. PMID: 23377670
  63. Identification of six new apoCIII isoforms with low-ppm mass measurement errors and ultrahigh precision. PMID: 23527852
  64. Measurement of plasma ApoCIII may improve CAD prediction in the general population PMID: 23173569
  65. The genetic determination of APOC3 might have an impact on a large portion of HIV-1-infected children at the time of choosing the treatment regimens or on the counter-measures against the adverse effects of drugs. PMID: 22848358
  66. High concentrations of ApoCIII are associated with increased triglycerides and decreased visceral fat mass in men with metabolic syndrome X. PMID: 18835943
  67. APOC3 -482TT genotype is independently associated with elevated fasting triglyceride concentrations in obese men PMID: 22004016
  68. APOC3 mRNA expression is increased in fatty liver and is regulated by SNPs in APOC3. The impact of the APOC3 SNPs on fatty liver is small and depends on visceral obesity PMID: 21829161
  69. Genetic variants in PNPLA3 but not APOC3 contribute to the variance in liver fat content due to non-alcoholic fatty liver disease. PMID: 22141340
  70. The ratio of plasma ApoCIII to ApoCII was significantly elevated in patients with severe preeclampsia relative to normotensive and gestational hypertensive individuals. PMID: 21321243
  71. the high-carbohydrate diet enhanced the adverse effect of the S2 allele on the triglyceride/high-density lipoprotein chlesterol ratio in the females of this cohort. PMID: 21603779
  72. Data suggest that APOC3 is up-regulated as early as the second trimester in women developing gestational diabetes. PMID: 22101237
  73. The lipoprotein fractions in the angina pectoris group had impaired antioxidant activity and increased triglycerides and apoC-III with structural and functional changes. PMID: 22211242
  74. APOC3 SNPs, alone or in combination, were not associated with insulin resistance, altered lipid levels, liver enzymes, and with liver damage (severity of steatosis, nonalcoholic steatohepatitis, and moderate/severe fibrosis) PMID: 21777557
  75. Our data did not support a relationship between the two polymorphisms of APOC3 gene and risk of coronary heart disease in the Han population in East China PMID: 22054125
  76. Mdm2 inhibited p53-mediated enrichment of HNF4alpha to the ApoCIII promoter while simultaneously reducing p53 binding and increasing recruitment of SHP to the ApoCIII promoter. PMID: 22197810
  77. High apolipoprotein CIII is associated with hypertriglyceridemia PMID: 22023023
  78. The risk of coronary heart disease contributed by LDL appeared to result to a large extent from LDL that contains apoC-III. PMID: 21986282
  79. The A allelic variant of the rs10892151 polymorphism is not associated with serum apo C-III concentration, but predisposes HIV-infected patients to less favorable lipid profile, particularly in those patients treated with protease inhibitors. PMID: 21939545
  80. there was no significant association between apolipoprotein C3 polymorphisms and fatty liver disease, lipid profiles, and insulin-resistance in Italian obese subjects PMID: 21663607
  81. genetic association studies in a young adult population in China: An SNP in APOC3 (482C>T) [along with SNP in APOA5 (1131T>C)] is associated with elevated TG and lipoprotein-TG levels induced by high carbohydrate/low fat diet, especially in females. PMID: 21646779
  82. polymorphisms in the apolipoprotein C-III gene are associated with dyslipidemia and increased risk of myocardial infarction PMID: 21499891
  83. lipid binding domain of apoC-III plays a key role in the formation of LLD for hepatic VLDL assembly and secretion PMID: 21676879
  84. Apolipoprotein C-III significantly affects the metabolism of the particle on which it resides, and in so doing, plays a central role in determining the concentration in the circulation of potentially atherogenic VLDL, IDL, and small dense LDL. PMID: 21421846
  85. Lean carriers of the -482T allele of the APOC3 promoter had increased type 2 diabetes risk, while such an effect was not observed in overweight participants. PMID: 21373834
  86. the relationship of smoking status on APOC3 -482C>T polymorphism and apolipoprotein C-III (apoC-III) concentrations;influence on risk of diabetes and coronary heart disease PMID: 21185820
  87. Data suggest that apoC-III attenuates the binding of apoE to the lipoprotein surface and apoE-mediated cellular uptake of lipoprotein remnants. PMID: 21080234
  88. Altered plasma apoC-III metabolism is a feature of dyslipidemia in moderate chronic kidney disease. PMID: 21297177
  89. The present study was undertaken to detect the association of the apoC-III 3238C>G polymorphism and several environmental factors with serum lipid profiles in the Guangxi Hei Yi Zhuang and Han populations. PMID: 20517165
  90. Glucose induces apoCIII transcription, which may represent a mechanism linking hyperglycemia, hypertriglyceridemia, and cardiovascular disease in type 2 diabetes. PMID: 21183731
  91. There is no causal relationship between variants in APOC3 and either increased hepatic triglyceride content or insulin resistance in middle-aged men and women. PMID: 21274868
  92. ApoC-III SNP (3238C>G): impact on blood lipid/lipoprotein levels (especially TG level) in conjunction with alcohol consumption; allelic frequency in China PMID: 20716347
  93. we demonstrated that increased plasma apoCIII concentration is associated with increased levels of small, dense LDL, a phenotype that confers increased cardiovascular disease risk PMID: 20303494
  94. an important structural element residing within the N-terminal region of apoC-III that governs the second step VLDL(1) maturation PMID: 20097930
  95. As a result of S. mansoni infection the glycosylation of a host protein is altered. PMID: 20071361
  96. Basal concentrations of apo C-III levels > or = 10.5 mg dL(-1) in coronary artery disease patients independently predicted cardiovascular mortality during the subsequent 5-year period and were associated with enhanced thrombin generation. PMID: 20002542
  97. central role for apoC-III in metabolic defects leading to hypertriglyceridemia PMID: 20368524
  98. The polymorphisms C-482T and T-455C in APOC3 are associated with nonalcoholic fatty liver disease and insulin resistance. PMID: 20335584
  99. the possible association between the APOA5 and APOC3 gene variants with plasma apolipoprotein A5 level in patients with metabolic syndrome was studied. PMID: 19932084
  100. expression of apoC-III in McA-RH7777 cells enhances hepatic triacylglycerol-rich VLDL assembly and secretion under lipid-rich conditions. PMID: 19622837

Show More

Hide All

Involvement in disease Hyperalphalipoproteinemia 2 (HALP2)
Subcellular Location Secreted
Protein Families Apolipoprotein C3 family
Tissue Specificity Liver.
Database Links

HGNC: 610

OMIM: 107720

KEGG: hsa:345

STRING: 9606.ENSP00000227667

UniGene: Hs.73849

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1